Metabolik sendrom: Önemi ve tedavisi

ÇAKMAK, Nazmiye; ÇAM, NEŞE

Metabolik sendrom: Önemi ve tedavisi

Nazmiye ÇAKMAK, (Dr. Siyami Ersek Göğüs Kalp ve Damar Cerrahisi Merkezi, Kardiyoloji Kliniği, İstanbul, Türkiye)

Neşe ÇAM (Dr. Siyami Ersek Toraks ve Kardiyovasküler Cerrahi Merkezi, Kardiyoloji Kliniği, İstanbul, Türkiye)

MN Kardiyoloji

0 0

Yıl: 2005 Cilt: 12 Sayı: 2 Sayfa Aralığı: 133 - 138 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Metabolik sendrom: Önemi ve tedavisi

Öz:

Her biri koroner kalp hastalığı (KKH) riskini artıran abdominal obezite, aterojenik dislipidemi, artmış kan basıncı ve insülin direncinden meydana gelen metabolik sendrom (MS), tüm dünyada giderek artan bir halk sağlığı sorunudur. NCEP kılavuzunun ATP III revizyonuna uygun bir şekilde beş unsurdan üçünün varlığı ile tanı konan MS, toplumumuzda 30 yaş üzerindeki erkek bireylerin %31'inde ve kadın bireylerin %43'ünde olmak üzere toplam 9.2 milyon erişkinimizde mevcuttur. Her 8 erişkinimizin 3'ünde MS var olup, her 6 erişkinimizin 1'i KKH için yüksek riske sahiptir. TEKHARF çalışması veritabanına göre KKH gelişiminin %53'ünden sorumlu tutulan MS, Türk toplumu için de oldukça önemli bir problemdir. Bu derlemede MS fizyopatolojisine kısaca değinilmiş, MS unsurlarının ve tedavi seçeneklerinin koroner kalp hastalığına olan etkileri klinik çalışmalar ışığında gözden geçirilmiştir.

Anahtar Kelime: Metabolik sendrom X Koroner hastalık

Konular: Endokrinoloji ve Metabolizma Kalp ve Kalp Damar Sistemi

Metabolic syndrome: Importance and treatment

Öz:

Metabolic syndrome (MS) is a public health problem which is becoming increasingly common worldwide. Factors characteristic of the MS are abdominal obesity, atherogenic dyslipidemia, high blood pressure and insulin resistance. Each factor is associated with increased risk for coronary heart disease (CHD). MS was defined in conformity with that proposed in the NCEP ATP III guidelines, namely in the presence of 3 out of 5 relevant components. This syndrome was identified in Turkish population in 31% of men and 43% of women with a total of 9.2 million adults. MS existed in 3 out of each 8 adults and 1 out of 6 adults have high risk for CHD. According to TEKHARF study, metabolic syndrome was present in 53% of patients with established CHD so metabolic syndrome is an important public health problem in Turkish people. In this review, the pathophysiology of the MS is summarized and effects of both the components and the treatment options of MS on coronary heart disease are reviewed with reference to clinical trials.

Anahtar Kelime: Metabolic Syndrome X Coronary Disease

Konular: Endokrinoloji ve Metabolizma Kalp ve Kalp Damar Sistemi

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

TRDizin Dışındaki Atıf Sayıları

OpenCitations: 0

OpenAlex: 0

Crossref: 0

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
2. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome.Diab Care 2001; 24:683-9.
3. Onat A, Sansoy V. Halkımızda koroner hastalığın başsuçlusu ;abolik sendrom: sıklığı, unsurları, koroner risk ile ilişkisi ve sek risk kriterleri. Türk Kardiyol Dern Arş 2002; 30:8-15.
4. Milani V. R, Lavie J. C. Prevalance and profile of metabolic drome in patients following acute coronary events and îcts of therapeutic lifestyle change with cardiac rehabilitation. J Cardiol 2003; 92:50-4.
5. Tchemof A, Lamarche B, Prud'Home D, et al. The dense L phenotype: association with plasma lipoprotein levels, eral obesity and hyperinsulinemia in men. Diabetes Care 36; 19:629-37.
6. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and. ■diovascular disease. J Clin Endocrinol Metab 2001; 86:713-18.
7. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose pression of tumor necrosis factor-alpha: direct role in obesity linked insulin resistance. Science 1993; 259:87-91.
8. Steppan CM, Bailey ST, Bhat S, et al. The hormon resistin ks obesity to diabetes. Nature 2001; 409:307-12.
9. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage Dduct of 30-kDa adipocyte complement-related protein creases fatty acid oxidation in muscle and causes weight loss mice. Proc Natl Acad Sci USA 2001; 98:2005-10.
10.Esposito K, Nicoletti G, Giagliano D. Obesity, cytokines and idothelial dysfunction. J Endocrinol Invest 2002; 25:646-9.
11.Yudkin JS, Stehouwer CDA, Emeis JJ, et al. C-reactive otein in healthy subjects: associations with obesity, insulin sistance and endothelial dysfunction: a potential role for rtokines originating from adipose tissue? Arterioscler Thromb ascBioM999; 19:972-8.
12.Ouchi N, Kihara S, Funahashi T, et al. Reciprocal ssociation of CRP with adiponectin in blood stream and dipose tissue. Circulation 2003; 107:671-4.
13.Fröhlich M, Imhof A, Berg G, et al. Association between C-jactive protein and features of the metabolic syndrome,liabetes Care 2000; 23:1835-9.
14.Rao SV, Donahue M, Pi-Sunyer X, Fuster V. Obesity as a risk actor in coronary artery disease. Am Heart J 2001; 142:1102-7.
15.Hokanson JE, Austin MA. Plasma/triglyceride level is a risk actor for cardiovascular disease independent of high-density poprotein cholesterol level: a meta-analysis of population-iased prospective studies. J Cardiovasc Risk 1996; 3:213-29.
16.Asman G, Cullen P, Schulte H. Prospective Cardiovascular funster Heart Study (PROCAM) results of follow-up at 8 years.Eur Heart J 1998; 19:A2-11.
l7.Ohlson LO, Larsson B, Svardsudd K, et al. The influence of body fat distribution on the incidence of diabetes mellitus: 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 1985; 34:1055-8.
18.Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974; 23:105-11.
19.Vaccaro O, Stamler J, Neaton JD. Sixteen-year coronary mortality in black and white men with diabetes screened for the Multipl Risk Factor Intervention Trial (MRFIT). Int J Epidemiol 1998; 27:636-41.
20.Sowers JR. Diabetes Mellitus and cardiovascular disease in women. Arch Intern Med 1998; 158:617-21.
21.Haffner SM, Lehto S, Rönnemaa T, Pyorala K, Laakso M.Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-34.
22.DIGAMI (Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction), theory and practice. Diabetes Obes Metab 2002; 4:289-95.
23.Stratton IM, Adler Al, Neil HA, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-12.
24.Beckman JA, Creager MA, Libby P. Diabetes and athero sclerosis: Epidemiology, pathophysiology and management.JAMA 2002; 287:2570-81.
25.Kannel WP. Blood pressure as a cardiovascular risk factor:prevention and treatment. JAMA 1996; 275:1571-6.
26.Wong ND, Cupples LA, Ostfeld AM, et al. Risk factors for long term coronary prognosis after initial myocardial infarction:the Framingham Study. Am J Epidemiol 1989; 130:469-80.
27.Blair SN, Kohl HW, Barlow CE, et al. Changes in physical fitness and all cause mortality: a prospective study of healthy and unhealthy men. JAMA 1995; 273:1093-8.
28.Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
29.Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343-50.
30.Clinical guidelines on the identification, evaluation and teatment of overweight and obesity in adults. The evidence report. Obes Res 1998; 6 (Suppl 2):51-209.
31.Rubins HB, Robins SJ, Conclusions from the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT).Am J Cardiol 2000; 86:543-4.
32.Stainer G. The Diabetes Atherosclerosis Intervention Study(DAIS): Relationship between low density lipoprotein particle size, plasma lipoproteins and progression of coronary artery disease. Circulation 2003; 107:1733-7.
33.Idzior-Walus B, Sieradzki J, Rostworowski W, et al. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrom X. Eur J Clin Invest 2000; 30:871-8.
34.Elam MB, Huninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT(Arterial Disease Multiple Intervention Trial) study: a randomized trial. JAMA 2000; 284:1263-70.
35.Grundy S, Cleeman J, Merz C, et al. Implications of recent clinical trials for the national cholesterol education program adult training panel III guidelines. Circulation 2004; 110:227-39.
36.Kommers R, Vrana A. Thiazolidinediones: tools for the research of metabolic syndrome X. Physiol Res 1998; 47:215-25.
37.Zimmet P. Addressing the insulin resistance syndrome: a role for the thiazolidinediones. Trends Cardiovasc Med 2002;12:354-62.
38.Blood Pressure Lowering Treatment Trialist's Collaboration.Effect of ACE inhibitors, calcium antagonists and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000; 356:1955-64.
39.Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE study. Lancet 2000; 355:253-9.
40.Benson SC, Pershadsingh HA, Ho Cl, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR gamma-modulating activity. Hypertension 2004;43:993-1002.
41.Grundy S, Hansen B, Smith S, et al. Clinical management of metabolic syndrome. Report of the American Heart Association/National Heart.Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109:551-6.

APA	ÇAKMAK N, ÇAM N (2005). Metabolik sendrom: Önemi ve tedavisi. , 133 - 138.
Chicago	ÇAKMAK Nazmiye,ÇAM NEŞE Metabolik sendrom: Önemi ve tedavisi. (2005): 133 - 138.
MLA	ÇAKMAK Nazmiye,ÇAM NEŞE Metabolik sendrom: Önemi ve tedavisi. , 2005, ss.133 - 138.
AMA	ÇAKMAK N,ÇAM N Metabolik sendrom: Önemi ve tedavisi. . 2005; 133 - 138.
Vancouver	ÇAKMAK N,ÇAM N Metabolik sendrom: Önemi ve tedavisi. . 2005; 133 - 138.
IEEE	ÇAKMAK N,ÇAM N "Metabolik sendrom: Önemi ve tedavisi." , ss.133 - 138, 2005.
ISNAD	ÇAKMAK, Nazmiye - ÇAM, NEŞE. "Metabolik sendrom: Önemi ve tedavisi". (2005), 133-138.

APA	ÇAKMAK N, ÇAM N (2005). Metabolik sendrom: Önemi ve tedavisi. MN Kardiyoloji, 12(2), 133 - 138.
Chicago	ÇAKMAK Nazmiye,ÇAM NEŞE Metabolik sendrom: Önemi ve tedavisi. MN Kardiyoloji 12, no.2 (2005): 133 - 138.
MLA	ÇAKMAK Nazmiye,ÇAM NEŞE Metabolik sendrom: Önemi ve tedavisi. MN Kardiyoloji, vol.12, no.2, 2005, ss.133 - 138.
AMA	ÇAKMAK N,ÇAM N Metabolik sendrom: Önemi ve tedavisi. MN Kardiyoloji. 2005; 12(2): 133 - 138.
Vancouver	ÇAKMAK N,ÇAM N Metabolik sendrom: Önemi ve tedavisi. MN Kardiyoloji. 2005; 12(2): 133 - 138.
IEEE	ÇAKMAK N,ÇAM N "Metabolik sendrom: Önemi ve tedavisi." MN Kardiyoloji, 12, ss.133 - 138, 2005.
ISNAD	ÇAKMAK, Nazmiye - ÇAM, NEŞE. "Metabolik sendrom: Önemi ve tedavisi". MN Kardiyoloji 12/2 (2005), 133-138.